MicroRNA-31 predicts the presence of lymph node metastases and survival in patients with lung adenocarcinoma

Clinical Cancer Research

Volumn 19, Issue 19, 2013, Pages 5423-5433

  Meng, Wei ^b,d   Ye, Zhenqing ^a   Cui, Ri ^c,d,f   Perry, James ^b,d   Dedousi Huebner, Vaia ^b   Huebner, Alexander ^b,d   Wang, Yao ^a   Li, Bin ^b,d   Volinia, Stefano ^c   Nakanishi, Hiroshi ^c,d   Kim, Taewan ^c,d   Suh, Sung Suk ^c,d   Ayers, Leona W ^e   Ross, Patrick ^c   Croce, Carlo M ^c,d   Chakravarti, Arnab ^b   Jin, Victor X ^a   Lautenschlaeger, Tim ^b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f YANBIAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

MICRORNA 31; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; COMPUTER MODEL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; RNA SEQUENCE; SIGNAL TRANSDUCTION; SURVIVAL PREDICTION; UPREGULATION;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC VECTORS; HUMANS; LENTIVIRUS; LUNG NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MICRORNAS; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NEOPLASM STAGING; PROGNOSIS; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84886420851     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0320     Document Type: Article

References (52)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Lagos-Quintana M, Rauhut R, Lendeckel W, Tuschl T. Identification of novel genes coding for small expressed RNAs. Science 2001;294: 853-8.
3. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell 2003;113:673-6.
4. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435:834-8.
5. Lu Y, Govindan R, Wang L, Liu PY, Goodgame B, Wen W, et al. MicroRNA profiling and prediction of recurrence/relapse-free survival in stage I lung cancer. Carcinogenesis 2012;33:1046-54.
6. Calin GA, Ferracin M, Cimmino A, Di Leva G, Shimizu M, Wojcik SE, et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005;353: 1793-801.
7. Yu SL, Chen HY, Chang GC, Chen CY, Chen HW, Singh S, et al. MicroRNA signature predicts survival and relapse in lung cancer. Cancer Cell 2008;13:48-57.
8. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M, et al. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 2006;9:189-98.
9. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H, et al. Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 2004;64:3753-6.
10. Gallardo E, Navarro A, Vinolas N, Marrades RM, Diaz T, Gel B, et al. miR-34a as a prognostic marker of relapse in surgically resected nonsmall-cell lung cancer. Carcinogenesis 2009:1903-9.
11. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487:330-7.
12. Bissels U, Wild S, Tomiuk S, Hafner M, Scheel H, Mihailovic A, et al. Combined characterization of microRNA and mRNA profiles delineates early differentiation pathways of CD133+ and CD34+ hematopoietic stem and progenitor cells. Stem Cells 2011;29:847-57.
13. Sarwate D, Sarkar S, Krimsky WS, Burgan CM, Patel K, Evans R, et al. Optimization of mediastinal staging in potential candidates for stereotactic radiosurgery of the chest. J Thorac Cardiovasc Surg 2012; 144:81-6.
14. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 2010;303:1070-6.
15. Bille A, Pelosi E, Skanjeti A, Arena V, Errico L, Borasio P, et al. Preoperative intrathoracic lymph node staging in patients with nonsmall-cell lung cancer: accuracy of integrated positron emission tomography and computed tomography. Eur J Cardiothorac Surg 2009;36:440-5.
16. Al-Sarraf N, Gately K, Lucey J, Wilson L,McGovern E, Young V. Lymph node staging by means of positron emission tomography is less accurate in non-small cell lung cancer patients with enlarged lymph nodes: analysis of 1,145 lymph nodes. Lung Cancer 2008;60:62-8.
17. Friedlander MR, Chen W, Adamidi C, Maaskola J, Einspanier R, Knespel S, et al. Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol 2008;26:407-15.
18. Martin M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnetjournal, North America 2011;17.
19. Marco A, Griffiths-Jones S. Detection of microRNAs in color space. Bioinformatics 2012;28:318-23.
20. Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods 2012;9:357-9.
21. Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 2010;26:139-40.
22. Griffiths-Jones S, Grocock RJ, van Dongen S, Bateman A, Enright AJ. miRBase: microRNA sequences, targets and gene nomenclature. Nucleic Acids Res 2006;34:D140-4.
23. Dweep H, Sticht C, Pandey P, Gretz N. miRWalk-database: prediction of possible miRNA binding sites by "walking" the genes of three genomes. J Biomed Informat 2011;44:839-47.
24. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-98.
25. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human MicroRNA targets. PLoS Biol 2004;2:e363.
26. Kruger J, Rehmsmeier M. RNAhybrid: microRNA target prediction easy, fast and flexible. Nucleic Acids Res 2006;34:W451-4.
27. Roy S, Chakravarty D, Cortez V, De Mukhopadhyay K, Bandyopadhyay A, Ahn JM, et al. Significance of PELP1 in ER-negative breast cancer metastasis. Mol Cancer Res 2012;10:25-33.
28. Cui R, Takahashi F, Ohashi R, Yoshioka M, Gu T, Tajima K, et al. Osteopontin is involved in the formation of malignant pleural effusion in lung cancer. Lung Cancer 2009;63:368-74.
29. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D, et al. miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010;12:247-56.
30. Valastyan S, Weinberg RA. miR-31: a crucial overseer of tumor metastasis and other emerging roles. Cell Cycle 2010;9:2124-9.
31. Choi YJ, Lin CP, Ho JJ, He X, Okada N, Bu P, et al. miR-34 miRNAs provide a barrier for somatic cell reprogramming. Nat Cell Biol 2011;13:1353-60.
32. Li Q, Wang G, Shan JL, Yang ZX, Wang HZ, Feng J, et al. MicroRNA-224 is upregulated inHepG2 cells and involved in cellular migration and invasion. J Gastroenterol Hepatol 2010;25:164-71.
33. Cekaite L, Rantala JK, Bruun J, Guriby M, Agesen TH, Danielsen SA, et al. MiR-9,-31, and-182 deregulation promote proliferation and tumor cell survival in colon cancer. Neoplasia 2012;14:868-81.
34. Valastyan S, Reinhardt F, Benaich N, Calogrias D, Szasz AM,WangZC, et al. A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell 2009;137:1032-46.
35. Liu X, Sempere LF, Ouyang H, Memoli VA, Andrew AS, Luo Y, et al. MicroRNA-31 functions as an oncogenic microRNA in mouse and human lung cancer cells by repressing specific tumor suppressors. J Clin Invest 2010;120:1298-309.
36. Strauss GM, Herndon JE 2nd, Maddaus MA, Johnstone DW, Johnson EA, Harpole DH, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-51.
37. Katz A, Saad ED. CALGB 9633: an underpowered trial with a methodologically questionable conclusion. J Clin Oncol 2009;27:2300-1; author reply 1-2.
38. Li Z, Yang CS, Nakashima K, Rana TM. Small RNA-mediated regulation of iPS cell generation. EMBO J 2011;30:823-34.
39. Hanina SA, Mifsud W, Down TA, Hayashi K, O'Carroll D, Lao K, et al. Genome-wide identification of targets and function of individualMicro-RNAs in mouse embryonic stem cells. PLoS Genet 2010;6:e1001163.
40. Dhillon AS, Hagan S, Rath O, Kolch W.MAPkinase signalling pathways in cancer. Oncogene 2007;26:3279-90.
41. Yang J, Weinberg RA. Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 2008;14: 818-29.
42. Cottonham CL, Kaneko S, Xu L. miR-21 and miR-31 converge on TIAM1 to regulate migration and invasion of colon carcinoma cells. J Biol Chem 2010;285:35293-302.
43. Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, et al. A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res 2011;17:6802-11.
44. Lautenschlaeger T, Meng W, Ye Z, Cui R, Perry J, Huebner A, et al. Lung adenocarcinoma microRNA-31 expression levels to predict lymph node metastasis and patient survival. J Clin Oncol 31, 2013 (suppl; abstr 7573).
45. Shin S, Dimitri CA, Yoon SO, Dowdle W, Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motifdependent signaling events. Mol Cell 2010;38:114-27.
46. Ha GH, Park JS, Breuer EK. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways. Cancer Lett 2013;332:63-73.
47. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Concurrent suppression of integrin alpha5, radixin, and RhoA phenocopies the effects of miR-31 on metastasis. Cancer Res 2010;70:5147-54.
48. Valastyan S, Chang A, Benaich N, Reinhardt F, Weinberg RA. Activation of miR-31 function in already-established metastases elicits metastatic regression. Genes Dev 2011;25:646-59.
49. Xu RS, Wu XD, Zhang SQ, Li CF, Yang L, Li DD, et al. The tumor suppressor gene RhoBTB1 is a novel target of miR-31 in human colon cancer. Int J Oncol 2012;42:676-82.
50. Lin PC, Chiu YL, Banerjee S, Park K, Mosquera JM, Giannopoulou E, et al. Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Res 2013;73:1232-44.
51. Liu X, Cheng Y, Chen X, Yang J, Xu L, Zhang C. MicroRNA-31 regulated by the extracellular regulated kinase is involved in vascular smooth muscle cell growth via large tumor suppressor homolog 2. J Biol Chem 2011;286:42371-80.
52. Butts CA, Ding K, Seymour L, Twumasi-Ankrah P, Graham B, Gandara D, et al. Randomized phase III trial of vinorelbine plus cisplatin compared with observation in completely resected stage IB and II nonsmall-cell lung cancer: updated survival analysis of JBR-10. J Clin Oncol 2010;28:29-34.